Asia-Pacific Interventional Cardiology and Peripheral Vascular Devices Market Segmentation, By Product (Angioplasty Balloons, Stent, Catheters, Aneurysm Repair Products, and Others and Accessories), Type (Conventional and Standard), Procedure (Peripheral Angioplasty, Iliac Intervention, Tibial (Below-The-Knee) Interventions, Arterial Thrombectomy, Peripheral Atherectomy, and Femoropopliteal Interventions), Indication (Peripheral Arterial Disease and Coronary Intervention), Age Group (Geriatric, Adults, and Pediatric ) End User (Hospitals, Ambulatory Surgery Centers, Nursing Facilities, Clinics and Others.), Distribution Channel (Third Party Distributors, Direct Tender, and Others) – Industry Trends and Forecast to 2031
Asia-Pacific Interventional Cardiology and Peripheral Vascular Devices Market Analysis
The term interventional cardiology is an area of medicine within the subspecialty of cardiology and peripheral vascular devices that uses enhanced, conventional, and advanced and other diagnostic techniques to evaluate blood flow and pressure in the coronary arteries and chambers of the heart, as well as technical procedures and medications to treat abnormalities that impair the function of the cardiovascular system. The interventional cardiology and peripheral vascular devices are used, since the devices make changes in sedentary lifestyle. It reduces the complications of chronic cardiac diseases, such as coronary artery disease, ischemic heart disease and vascular diseases. The Asia-Pacific Interventional Cardiology and Peripheral Vascular Devices Market is experiencing robust growth driven by an aging population, rising rates of cardiovascular diseases, and advancements in minimally invasive techniques. Here is a detailed analysis:
Interventional Cardiology and Peripheral Vascular Devices Market Size
Asia-Pacific interventional cardiology and peripheral vascular devices market size was valued at USD 2.70 billion in 2023 and is projected to reach USD 5.16 billion by 2031, with a CAGR of 8.4% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.
Interventional Cardiology and Peripheral Vascular Devices Market Trends
“Growing Awareness About Cardiovascular Health and The Increasing Availability of Treatment Options”
Rising awareness of cardiovascular health and increased treatment options are key drivers of the interventional cardiology and peripheral vascular devices market in the Asia-Pacific region. As public understanding of cardiovascular diseases (CVDs) grows, more individuals recognize the importance of heart health and the risks associated with these conditions, leading to higher demand for preventive measures, regular check-ups, and effective treatments. Educational initiatives by governments, healthcare organizations, and non-profits are promoting awareness of CVD risk factors, encouraging proactive healthcare behaviors. This cultural shift is boosting demand for interventional devices like stents, catheters, and balloons essential for diagnosing and treating cardiovascular issues.
Report Scope and Interventional Cardiology and Peripheral Vascular Devices Market Segmentation
|
Attributes
|
Anti-Nuclear Antibody Test Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
China, India, Japan, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, and Rest of Asia-Pacific
|
|
Key Market Players
|
Abbott (U.S.), Boston Scientific Corporation (U.S.), BD (U.S.), Medtronic (U.S.), Terumo Corporation (Japan), B.Braun SE (Germany), ENDOCOR GmbH & CO. KG (Germany), Teleflex Incorporated (U.S.), Lepu Medical Technology (Beijing)Co.,Ltd. (China), MicroPort Scientific Corporation (China), Koninklijke Philips N.V. (Netherlands), Biotronik (Germany), SMT (China), OrbusNeich Medical Group Holdings Limited (China), Biosensors International Group, Ltd. (Singapore), Edwards Lifesciences Corporation (U.S.), AngioDynamics (U.S.), Alvimedica (Turkey), Cook (U.S.), Cordis (U.S.), Palex (Spain), and W. L. Gore & Associates (U.S.), Inc.
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.
|
Interventional Cardiology and Peripheral Vascular Devices Market Definition
Interventional cardiology is a branch of cardiology dealing with catheter-based treatment of heart diseases, such as coronary artery disease, heart valve diseases, and structural heart issues. Peripheral vascular devices are used to treat peripheral artery diseases, aneurysms, and other vascular disorders outside the heart, typically affecting arteries, veins, and lymphatic systems in areas like the legs and arms.
Interventional Cardiology and Peripheral Vascular Devices Market Dynamics
Drivers
- Increasing Prevalence of Autoimmune Diseases Across the Globe
The Asia-Pacific region is seeing a sharp increase in cardiovascular diseases (CVDs), influenced by lifestyle shifts, urbanization, and a growing elderly population. Rising sedentary behaviors, poor diets, smoking, alcohol use, and stress are contributing to higher obesity rates and conditions like hypertension, diabetes, and dyslipidemia, all of which increase CVD risk. Additionally, with one of the world’s fastest-aging populations, age-related vulnerabilities to heart disease are more common. These trends are transforming healthcare needs and driving demand for interventional cardiology and vascular devices to manage and treat CVDs effectively.
For instance,
In August 2024, according to an article published by THE LANCET, between 2025 and 2050, crude cardiovascular mortality is projected to rise by 91.2%, despite a 23% decline in the age-standardized mortality rate (ASMR). Ischaemic heart disease and stroke will remain the top causes, with Central Asia’s ASMR reaching 676 deaths per 100,000, far above Asia's average of 186, and high-income Asia at just 22. High systolic blood pressure will lead ASMR causes across Asia, while high fasting plasma glucose will dominate in Central Asia, contributing to 546 deaths per 100,000. These trends highlight the need for intervention, fueling demand for interventional cardiology and vascular devices across Asia-Pacific
In August 2024, according to an article published by THE LANCET, the cardiovascular disease (CVD) epidemic is particularly severe in Asia, accounting for 60% of the 18.6 million global CVD deaths in 2019. By 2050, the region's CVD prevalence is projected to rise by 109% from 2025, reaching 729.5 million cases. Ischaemic heart disease, peripheral artery disease, and stroke will make up 86.8% of cases, with heart failure affecting 74.5 million people. This surge underscores the urgent need for effective treatment and is expected to boost demand for interventional cardiology and vascular devices in Asia-Pacific healthcare systems
The interplay of lifestyle changes, an aging population, heightened awareness, and technological innovations is expected to sustain and enhance the demand for interventional devices. As healthcare providers continue to prioritize cardiovascular health and invest in advanced treatment solutions, the market for interventional cardiology and peripheral vascular devices is projected to grow substantially, addressing the urgent healthcare needs posed by the increasing burden of cardiovascular diseases in the region.
- Expansion of Diagnostic Centers and Laboratories
The growing geriatric population in the Asia-Pacific region is a significant driver of the interventional cardiology and peripheral vascular devices market. As older adults age, the prevalence of cardiovascular diseases (CVDs) rises, necessitating specialized medical devices to address their unique needs. Older adults are particularly susceptible to CVDs due to age-related changes and risk factors like hypertension, diabetes, and hyperlipidemia, increasing the demand for interventional devices such as stents and catheters. Furthermore, the elderly population's growth is leading to a rise in demand for invasive procedures and a proactive approach to cardiovascular health, enhancing the utilization of diagnostic and therapeutic devices and driving market expansion.
For instance,
In May 2024, according to an article published by Asian Development Bank, the population aged 60 and older in developing Asia and the Pacific is projected to nearly double to 1.2 billion by 2050. This dramatic rise in the elderly population highlights the increasing need for specialized healthcare services to address age-related health issues. As the geriatric population expands, it is expected to significantly drive growth in the Asia-Pacific interventional cardiology and peripheral vascular devices market, as healthcare systems focus on delivering effective treatments for conditions prevalent among older adults, particularly cardiovascular diseases
In September 2023, according to an article published by The Hindu, India’s elderly population is growing at a decadal rate of 41%, with the share of seniors expected to double to over 20% of the total population by 2050.
As the number of elderly individual’s increases, so does the prevalence of cardiovascular diseases, which results in heightened demand for specialized medical devices and interventional procedures. With an emphasis on preventive healthcare and ongoing technological innovations, the market is expected to experience substantial growth, effectively addressing the unique healthcare needs of the aging population and improving patient outcomes in cardiovascular care.
Opportunities
- Increasing Collaboration and Partnerships
Increasing collaboration and partnerships among companies in the Asia-Pacific interventional cardiology and peripheral vascular devices market create significant opportunities for growth and innovation. By forming strategic alliances, medical device manufacturers can improve distribution channels and market access, allowing for faster introduction of innovative products in clinical settings. These collaborations help companies understand the specific needs of healthcare providers and patients, enabling them to tailor their products to local market dynamics and regulatory requirements. Additionally, joint efforts can lead to co-development initiatives, fostering innovation and speeding up the time-to-market for new technologies.
For instance,
In September 2021, Medtronic announced that the company collaborated with Mpirik, which is known to provide a suite of cloud-based automated patient screening and care pathways for cardiovascular diseases. This collaboration helps the company to address disparities in care associated with the prevention of sudden cardiac arrest with their advanced artificial intelligence platform, thereby aiding the company to improve their leadership in market further
The trend of increasing collaboration and partnerships, along with a focus on timely product launches, offers substantial opportunities for growth in the Asia-Pacific interventional cardiology and peripheral vascular devices market. By harnessing these catheters, companies can enhance patient care, improve clinical outcomes, and strengthen their competitive positions in a rapidly evolving healthcare environment..
- Increasing Investment in Research & Development
Rising R&D investments offer crucial growth opportunities for the Asia-Pacific interventional cardiology and peripheral vascular devices market. With the increasing prevalence of cardiovascular diseases, demand for innovative treatment solutions is surging. By focusing on R&D, companies can develop advanced technologies, like bioabsorbable materials and minimally invasive devices, improving patient outcomes and addressing current treatment gaps. Moreover, R&D investment promotes collaboration with academic and research institutions, accelerating the translation of innovations into clinical use. These advancements not only enhance healthcare delivery efficiency but also strengthen market competitiveness by meeting the evolving needs of providers and patients.
For instance,
In July 2021, Abbott announced that the company confirms to invest USD 41.19 million for R&D for projects that focus on next-generation stents as well as coronary and endovascular balloon technologies for interventional cardiology treatments. This investment was specifically provided for their Clonmel facility in Ireland, which is a new research and development program in the area of cardiovascular devices.
By prioritizing research and innovation, companies can develop ground-breaking products that not only address the challenges posed by cardiovascular diseases but also enhance patient care. As the market continues to grow, the emphasis on R&D will be crucial for stakeholders looking to capitalize on emerging trends, ultimately leading to improved health outcomes and increased market competitiveness in the region.
Restraints/Challenges
- High Cost of Barrier
The high cost of advanced interventional devices significantly restrains the interventional cardiology and peripheral vascular devices market in the Asia-Pacific region. While these innovations enhance patient outcomes, their steep prices limit accessibility, particularly in lower-income areas.
Constrained healthcare budgets make it difficult for public systems to fund expensive technologies, leading hospitals to opt for cheaper alternatives, especially in rural regions. This results in delayed interventions and poorer health outcomes. Additionally, high costs deter providers from investing in necessary training and infrastructure, further limiting advanced cardiovascular care and reducing demand for these treatments, hindering market growth.
For instance,
According to IndiaMART, the AngioSculpt RX PTCA scoring balloon catheter brings a transformative solution for treating CAD, being the only specialty scoring device approved for ISR and complex Type-C lesions. Priced at USD 4.81, it represents a premium option in the market.
This highlights the “high cost of balloon catheters,” which poses a restraint on the Asia-Pacific interventional cardiology and peripheral vascular devices market, as such premium pricing may limit accessibility and broader use, especially in cost-sensitive healthcare settings
- Risks Associated with Interventional Cardiology and Peripheral Vascular Devices
Interventional cardiology and peripheral vascular devices come with risks like infections, bleeding, vessel damage, and allergic reactions, along with potential device malfunctions and complications such as thrombosis or restenosis, which can necessitate further medical interventions. These risks can hinder healthcare providers from adopting new technologies, especially in regions with limited clinical expertise. The learning curve for advanced devices like Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) is steep, and inadequate training increases the chance of procedural errors, further discouraging adoption. Additionally, concerns about legal liabilities and patient safety issues slow the integration of these technologies into practice.
For instance,
In February 2021, according to an article published by PubMed Central, recent antithrombotic treatment trials have indicated that patients in the Asia-Pacific region are more prone to bleeding complications, such as gastrointestinal bleeding and hemorrhagic stroke. These heightened risks pose a challenge for interventional cardiology and peripheral vascular devices, as the necessity for anticoagulation during procedures raises safety concerns. Consequently, both physicians and patients may be reluctant to adopt these advanced treatments, which hinders the uptake of innovative devices and slows market growth in the region
The risks associated with the use of interventional cardiology and peripheral vascular devices act as a significant restraint on the Asia-Pacific market by slowing down the adoption of innovative solutions. Concerns over safety, training limitations, and potential legal liabilities make healthcare providers hesitant, impeding the market’s growth despite advancements in device technology.
Interventional Cardiology and Peripheral Vascular Devices Market Scope
The market is segmented on the basis product, type, procedure, indication, age group, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Angioplasty Balloons
- Old/Normal Balloons
- Drug Eluting Balloons
- Cutting And Scoring Balloons
- Stents
- Angioplasty Stents
- Coronary Stents
- Bare-Metal Stents
- Drug-Eluting Stents (Des)
- Bio Absorbable Stents
- Peripheral Stents
- Others
- Catheters
- Product
- Guiding Catheters
- Micro Catheters
- Cto Catheters
- Specialty
- Angiography Catheter
- Coronary Aspiration Catheter
- Others
- Product
- Aneurysm Repair Products
- Neuro Aneurysm (Coiling)
- Others
- Others And Accessories
- Guidewires
- Introducer Sheaths
- Balloon Inflation Devices
- Vascular Closure Devices
- Others
- Others And Accessories
Type
- Conventional
- Stents
- Catheters
- Guidewires
- Vascular Closure Devices (Vcds)
- Others
- Advanced
- Balloon Catheters
- Stent Grafts
Procedure
- Peripheral Angioplasty
- Angioplasty Balloons
- Stent
- Catheters
- Aneurysm Repair Products
- Others And Accessories
Indication
- Peripheral Arterial Disease
- Atherosclerosis
- Neuro Aneurysm (Coiling)
- Lower Extremity Peripheral Arterial Disease
- Supra-Inguinal Arterial Disease
- Infra-Inguinal Arterial Disease
- Infra-Popliteal Disease
- Upper Extremity Occlusive Disease
- Carotid Artery Disease
- Others
- Coronary Intervention
- Ischemic Heart Disease
- Thoracic Aortic Aneurysm
- Valve Disease
- Percutaneous Valve Repair or Replacement
- Congenital Heart Abnormalities
- Others
Age Group
- Geriatric
- Adults
- Pediatric
End User
- Hospitals
- Private
- Public
- Ambulatory Surgery Centers
- Nursing Facilities
- Clinics
- Others
Distribution Channel
- Third Party Distributors
- Direct Tender
- Others
Interventional Cardiology and Peripheral Vascular Devices Market Regional Analysis
The market is analyzed and market size insights and trends are provided by country, product, type, procedure, indication, age group, end user, and distribution channel as referenced above.
The countries covered in the market are China, India, Japan, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, and rest of Asia-Pacific.
China is expected to dominate the market due to the region's advanced healthcare infrastructure, high prevalence of cardiac diseases, and increasing adoption of early treatment devices.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Interventional Cardiology and Peripheral Vascular Devices Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Interventional Cardiology and Peripheral Vascular Devices Market Leaders Operating in the Market Are:
- Abbott (U.S.)
- Boston Scientific Corporation (U.S.)
- BD (U.S.)
- Medtronic (U.S.)
- Terumo Corporation (Japan)
- B.Braun SE (Germany)
- ENDOCOR GmbH & CO. KG (Germany)
- Teleflex Incorporated (U.S.)
- Lepu Medical Technology (Beijing)Co.,Ltd. (China)
- MicroPort Scientific Corporation (China)
- Koninklijke Philips N.V. (Netherlands)
- Biotronik (Germany)
- SMT (China)
- OrbusNeich Medical Group Holdings Limited (China)
- Biosensors International Group, Ltd. (Singapore)
- Edwards Lifesciences Corporation (U.S.)
- AngioDynamics (U.S.)
- Alvimedica (Turkey)
- Cook (U.S.)
- Cordis (U.S.)
- Palex (Spain)
- W. L. Gore & Associates (U.S.)
Latest Developments in Interventional Cardiology and Peripheral Vascular Devices Market
- In September 2024, Abbott and Seed Global Health are partnering to enhance maternal and child healthcare in Malawi. Their initiative includes establishing a Maternal Health Center of Excellence at Queen Elizabeth Central Hospital, focusing on training health workers to improve care quality and sustainability
- In September 2024, BD completed its acquisition of Edwards Lifesciences' Critical Care product group, renaming it BD Advanced Patient Monitoring. This move expanded BD's portfolio with advanced monitoring technologies and AI-enabled clinical tools, enhancing its smart connected care solutions and supporting future innovations in patient care
- In March 2024, Medtronic has received FDA approval for its latest Evolut FX+ TAVR system, designed to treat symptomatic severe aortic stenosis. This new generation features a modified diamond-shaped frame that offers larger coronary access windows, enhancing catheter maneuverability while maintaining the exceptional valve performance and strength associated with the Evolut platform
- In March 2024, Abbott has extended its partnership with Real Madrid and the Real Madrid Foundation through the 2026-27 season, focusing on combating childhood malnutrition and promoting healthy habits. The collaboration has provided extensive nutrition education and screening for millions of children worldwide
- In November 2023, Boston Scientific Corporation concluded its acquisition of Relievant Medsystems on November 17, 2023, adding the Intracept Intraosseous Nerve Ablation System to its chronic pain portfolio. The acquisition, costing USD 850 million upfront plus contingent payments, expands access to vertebrogenic pain treatment through national coverage, benefiting over 150 million lives
- In November 2023, BD and Bio Farma signed a memorandum of understanding to combat tuberculosis in Indonesia by providing access to BD's TB diagnostics. This collaboration aimed to optimize the supply chain and enhance TB diagnosis, aligning with Indonesia’s goal to eliminate the disease by 2030
- In September 2023, Boston Scientific Corporation announced it had entered into an agreement to acquire Relievant Medsystems, Inc.for USD 850 million upfront, plus contingent payments. The acquisition, expected to close in early 2024, aimed to enhance Boston Scientific's chronic low back pain treatment portfolio with the Intracept system.
SKU-